TY - JOUR AB - Purpose Competition is tremendously increasing in all business areas, among which the pharmaceutical sector is one of the most profitable fields. Accordingly, an important research effort is to examine whether competitiveness in pharmaceutical markets follows the same rules. The purpose of this paper is to evaluate competitive strategies in this industry and present a proper framework.Design/methodology/approach To this end, a conceptual model of competitive strategies including cost leadership, quality and differentiation was designed based on previously proposed models in the literature. More precisely, the framework was established with the consideration of the pharmaceutical’s specific requirements. For testing the practicality the model, a questionnaire was designed and 80 generic pharmaceutical companies in Iran were selected as the statistical sample and effects of each strategy on export performance was evaluated. The questionnaires were distributed to senior managers and filled through in-person interviews. The collected data were analyzed using binomial, partial least square, confirmatory factor analysis and Friedman tests.Findings Among the strategies under investigation, cost leadership strategy had the strongest effects, while quality ranked second. The proposed framework can also be used for the evaluation of pharmaceutical companies’ export readiness. The results demonstrated that export readiness of the pharmaceutical companies was not desirable.Originality/value The ideas in this paper, which have untold value for pharmaceutical industries, are unique to competitive strategies in export marketing. VL - 13 IS - 3 SN - 1750-6123 DO - 10.1108/IJPHM-02-2018-0011 UR - https://doi.org/10.1108/IJPHM-02-2018-0011 AU - Mohammadzadeh Mehdi AU - Bakhtiari Nima AU - Safarey Reza AU - Ghari Tayebeh PY - 2019 Y1 - 2019/01/01 TI - Pharmaceutical industry in export marketing: a closer look at competitiveness T2 - International Journal of Pharmaceutical and Healthcare Marketing PB - Emerald Publishing Limited SP - 331 EP - 345 Y2 - 2024/04/25 ER -